Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] Summary by Category - **Regulatory Approval** - The company has obtained the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride, indicating compliance with national regulations [1] - **Research and Development Investment** - The total R&D investment for this drug has reached 3.7558 million RMB (approximately 0.37558 million) as of the date of the announcement [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its sodium chloride injection of tirofiban hydrochloride, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The wholly-owned subsidiary Anhui Double Crane Pharmaceutical Co., Ltd. is responsible for the newly approved drug [1] - The drug is indicated for adult patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) who experience chest pain within 12 hours and have ECG changes and/or elevated myocardial enzymes [1] - The drug is also used for patients with ST-segment elevation myocardial infarction (STEMI) undergoing planned direct percutaneous coronary intervention (PCI) to reduce the occurrence of major cardiovascular events [1]

Group 1 - China Shipbuilding has completed the share swap absorption merger with China Shipbuilding Industry Corporation, with 3.053 billion new shares listed on September 16, 2025 [1] - Transsion Holdings' shareholder plans to transfer 2% of the company's shares, amounting to approximately 22.807 million shares [1] Group 2 - Chipone Technology reported a record high in new orders from July 1 to September 11, 2025, totaling 1.205 billion yuan, with AI computing orders accounting for about 64% [2] - Chipone Technology's total order amount reached 3.025 billion yuan by the end of the second quarter of 2025, indicating a significant increase [2] Group 3 - Chipone Technology plans to acquire 97.0070% equity of Chipai Technology through a combination of share issuance and cash payment, with the stock resuming trading on September 12 [3] Group 4 - Xinjun Network received a notice of share reduction from its major shareholder, Shanghai Senxiao Investment Center, which reduced its holdings by 1.6271 million shares, bringing its ownership down to 5.29% [4] Group 5 - Yangjie Technology intends to acquire 100% equity of Better Electronics for 2.218 billion yuan, with a profit commitment of no less than 555 million yuan from 2025 to 2027 [5] Group 6 - Shoukai Co. announced that its subsidiary, Yingxin Company, indirectly holds approximately 0.3% equity in Yushu Technology, indicating a low ownership stake [6] Group 7 - Xiamen Airport reported a total passenger throughput of 2.707 million in August, representing a year-on-year increase of 5.18% [9] - *ST Tianshan experienced a significant decline in livestock sales revenue, down 95.80% year-on-year in August [9] Group 8 - Taihe Intelligent's shareholder plans to transfer 5.79% of the company's shares to Sunshine New Energy [9] - Jilin Expressway's subsidiary won a construction project worth 9.592 billion yuan [9] - Tianyong Intelligent secured a project with SAIC Group for engine assembly line renovation [9]

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. (上海长征富民金山制药有限公司), has received the approval notice from the National Medical Products Administration for the supplementary application of peritoneal dialysis solution (Lactate-G1.5%) and peritoneal dialysis solution (Lactate-G2.5%) [1] Company Summary - The approval pertains to two specific products related to peritoneal dialysis, indicating a potential expansion in the company's product offerings in the medical field [1] - This development may enhance the company's market position in the healthcare sector, particularly in renal care solutions [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－081 华润双鹤药业股份有限公司 关于全资子公司上海长征富民金山制药有限公司 腹膜透析液(乳酸盐)系列药品获得 药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公 司上海长征富民金山制药有限公司(以下简称"上海长富")收到了国 家药品监督管理局(以下简称"国家药监局")颁发的腹膜透析液(乳酸 盐-G1.5%)、腹膜透析液(乳酸盐-G2.5%)(以下简称"该系列药品") 《药品补充申请批准通知书》。现将相关情况公告如下： 一、通知书主要内容 | 药品名称 | 药品通用名称： 腹膜透析液(乳酸盐-G1.5%) | 英文名/拉丁名： | | --- | --- | --- | | | 腹膜透析液(乳酸盐-G2.5%) | PeritonealDialysisSolution(Lactate-G1.5%) PeritonealDialysisSolution(Lactate-G2. ...

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu"), has received the approval notice for the supplementary application of peritoneal dialysis solution (lactate-G1.5%) and peritoneal dialysis solution (lactate-G2.5%) from the National Medical Products Administration (NMPA) [1] Group 1 - The peritoneal dialysis solution (lactate) is primarily used for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis therapy [1] - The approval of the supplementary application for the peritoneal dialysis solution (lactate) represents an enhancement of the product specifications, which is expected to benefit the future market sales and competitive potential of this product series [1]

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinsan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu"), received the Drug Supplement Application Approval Notice from the National Medical Products Administration for peritoneal dialysis solutions (lactate-G1.5% and lactate-G2.5%) [1] Group 1 - The peritoneal dialysis solutions (lactate) are primarily suitable for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis therapy [1] - The approval of the Drug Supplement Application is a further enhancement of the specifications for the peritoneal dialysis solutions (lactate), which will benefit the future market sales and competitive potential of this product series [1]

Group 1 - The core point of the article is that China Resources Double Crane has received approval from the National Medical Products Administration for its peritoneal dialysis solution, indicating a significant development in its product portfolio [1] - The peritoneal dialysis solution is primarily used for patients with acute and chronic renal failure, highlighting the company's focus on critical healthcare needs [1] - The company has invested a total of 1.2174 million yuan in research and development for this product, reflecting its commitment to innovation in the pharmaceutical sector [1] Group 2 - The global market size for peritoneal dialysis solutions (lactate) is projected to be approximately 5.62 billion USD in 2024, indicating a substantial market opportunity [1] - The domestic sales total for peritoneal dialysis solutions is estimated at 2.78 billion yuan, showcasing the potential for growth in the local market [1] - China Resources Double Crane's sales revenue from this product line is reported at 317 million yuan, capturing a market share of 14%, which positions the company competitively within the industry [1]

法律意见书 北京市中伦律师事务所 关于华润双鹤药业股份有限公司 2025 年第二次临时股东会的 法律意见书 致：华润双鹤药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事证券法律业 务管理办法》等法律、法规和规范性文件以及《华润双鹤药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，北京市中伦律师事务所（以下简称"本 所"）作为华润双鹤药业股份有限公司（以下简称"公司"）的常年法律顾问， 指派律师出席公司 2025 年第二次临时股东会（以下简称"本次股东会"），并 依法出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序是否符合法律、行政法规 及《公司章程》的规定，以及出席本次股东会人员的资格、召集人资格、会议表 决程序及表决结果是否合法有效发表意见，而不对本次股东会所审议的议案内 容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发表意 见。本次股东会通过网络投票系统进行投票的股东资格由网络投票系统提供机 构验证其身份。 为出具本法律意见书，本所律师列席了本次股东会，并根据有关法律、法 ...

2025 年第二次临时股东会 2025 年 9 月 9 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-080 一、会议召开和出席情况 华润双鹤药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (一) 股东会召开的时间：2025 年 9 月 9 日 (二) 股东会召开的地点：北京市朝阳区锐创国际中心 A 座 9 层 会议室 (三) 出席会议的普通股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 467 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 637,745,280 | | 3、出席会议的股东所持有表决权股份数占公司有 | 61.3950 | | 表决权股份总数的比例(%) | | (四) 表决方式是否符合《公司法》及公司《章程》的规定，股东 会主持情况等。 1、会议采取现场及网络方式投票表决，表决程序符合《公司法》 和公司《章程》的规定。 2、 ...